Xenical Efficacy In "Mildly Overweight" Subjects Questioned By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline has proposed to market over-the-counter orlistat under the trade name Alli.
You may also be interested in...
Xenical Switch Proposal Slated For Advisory Committee Review In January
FDA’s Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees will meet Jan. 23 to review GSK’s application for over-the-counter use of 60 mg orlistat.
Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products
FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation
Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products
FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation